Key result
Sildenafil co-administration lowers glimepiride bioavailability and reduces hypoglycemia in diabetic nephropathy rats.
Why the study?
Does Sildenafil Citrate alter the pharmacokinetics and hypoglycemic effect of Glimepiride in rats with diabetic nephropathy?
Does Sildenafil Citrate alter the pharmacokinetics and hypoglycemic effect of Glimepiride in rats with diabetic nephropathy?
Co-administration of sildenafil with glimepiride in a rat model of diabetic nephropathy alters glimepiride pharmacokinetics and reduces its hypoglycemic effect over 6 weeks.
Answers are grounded in this paper and cite their sources.
Potential interaction in diabetic nephropathy warrants human PK studies; leaves open clinical relevance in patients.
The present study investigate the drug interaction of Glimepiride (GLIM) with Sildenafil Citrate (SIL) in Diabetic Nephropathy (DN) rats. Diabetes was induced in rats by administering Streptozotacin i. e. STZ (60 mg/kg). In present investigation GLIM (0.5 mg/kg, P.O.) and SIL (2.5 mg/kg, P.O.) were given for 6 weeks after the confirmation of DN. Pharmacodynamic and kinetic parameters were estimated after 1(st) dose and at the end of 6(th) week of drug administration. There was significant (p<0.001) increase in the bioavailability of GLIM in the presence of SIL in DN after the 1(st) dose of administration of the drug as compared to GLIM treated rat, whereas at the end of 6(th) week of drug administration, there were significant (p<0.0001) decrease in the bioavailability of GLIM+SIL treated DN rats compared to GLIM treated rats. There was significant (P<0.01) reduction of blood glucose level in GLIM+SIL treated group as compare to only GLIM treated group on 1(st) dose of drug administration but after continuous treatment for next 6 weeks, GLIM treated group showed significant hypoglycemia which was found to be reduced in GLIM+SIL treated group significantly. The present study concluded that GLIM+SIL treatment reduces the hypoglycemic condition which was there for GLIM treated DN rat.
No takes yet. Share an insight, caveat, or question.
Tripathi et al. (2014) studied Diabetic Nephropathy (in rats). Glimepiride + Sildenafil Citrate vs. Glimepiride alone was evaluated on Bioavailability of Glimepiride and blood glucose level (p=<0.0001). Co-administration of Glimepiride and Sildenafil Citrate in diabetic nephropathy rats decreased Glimepiride bioavailability at 6 weeks and reduced hypoglycemia.
Synapse has enriched 10 related papers. Consider them for comparative context: